Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03011931 · ClinicalTrials.gov registry record · Early Phase 1

Simvastatin Metabolism as a Test for CD Activity (IRB 15-007568]

A Early Phase 1 study of Celiac Disease, sponsored by Entero Therapeutics.

Completed
Registry status
Early Phase 1
Development phase
40
Enrollment target
1
Study location

NCT03011931 is a Early Phase 1 study of Celiac Disease that has completed, run by Entero Therapeutics. The registered enrollment target is 40 participants, below the 1,978-participant average among 24 other Celiac Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03011931, a Early Phase 1 study of Celiac Disease, has completed, sponsored by Entero Therapeutics.

COMPLETED
Registry status
Early Phase 1
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

To study the correlation between simvastatin metabolism by the enterocyte and the histologic state of the intestine in treated celiac disease.

Conditions Studied

Celiac Disease

Interventions

  • DRUG Simvastatin

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2016-03
Est. Completion 2019-02
Phase Early Phase 1

Sponsor

Entero Therapeutics

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03011931

The ClinicalTrials.gov registry entry for NCT03011931 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,978-participant average among 24 other Celiac Disease trials with a reported enrollment target (98% lower). The listed sponsor is Entero Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Celiac Disease appearing as the primary indexed condition, and to 1 intervention - of which Simvastatin is the first listed.

NCT03011931 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT03011931 about?

NCT03011931 is a clinical study titled "Simvastatin Metabolism as a Test for CD Activity (IRB 15-007568]". To study the correlation between simvastatin metabolism by the enterocyte and the histologic state of the intestine in treated celiac disease.

What is the current status of trial NCT03011931?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 40 participants. The study started on 2016-03. Estimated completion is 2019-02.

What conditions does trial NCT03011931 study?

This clinical trial studies the following conditions: Celiac Disease.

What interventions are being tested in trial NCT03011931?

The interventions under investigation include: Simvastatin (DRUG).

Who is sponsoring clinical trial NCT03011931?

This trial is sponsored by Entero Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03011931 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Celiac Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Celiac Disease

All registered trials for this condition

Minnesota

All trials with a study site in Minnesota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.